NPR's Robert Siegel speaks with our regular political commentators E.J. Dionne of The Washington Post and Brookings Institution and David Brooks of The New York Times. They discuss Rep. Kevin McCarthy's decision to withdraw from the race for the next Speaker of the House, Hillary Clinton's opposition to the TPP, and the Russian strategy in Syria.
Some daily fantasy sports players are dropping their business after a DraftKings employee with access to potentially valuable data won $350,000 at rival company FanDuel. The two companies this week banned their workforce from playing fantasy for cash, and they say more regulation is not needed; they will police themselves. But regulators are asking questions about the fast-growing industry.
One of the surest signs of an economic bubble that is about to pop is a surge in the stock price of Sotheby's. The global art dealer's stock resembles a rollercoaster, and it has predicted every up and down of the global economy since the company went public. So with talk of big bubbles in the tech sector, Planet Money went poking around.
In an interview with New Yorker writer Emily Nussbaum Wednesday, NPR mistakenly characterized a segment on the The Late Show with Stephen Colbert as paid product placement. Both Taco Bell and Ben & Jerry's say they had nothing to do with the segment.
Officials from the Treasury, Commerce, and State Departments visit Cuba this week to grasp a better understanding of the country's economy. They want to know how far the U.S. can go in doing business with Cuba under the limits of the half-century old embargo. Commerce Secretary Penny Pritzker led the delegation, despite criticism from those who say the move comes too soon.
A big sticking point in the negotiations over the Trans-Pacific Partnership involved biologics medicines and vaccines created from living organisms. The dispute centered on patent protection: how many years drug companies should have before facing competition from generics. The negotiators ended up with a complicated compromise that gives drug makers five to eight years of protection. But nobody is really happy with the outcome.